Blood cancer refers to the 130+ types of cancer and related disorders of the blood, bone marrow or lymph nodes, including leukemia, lymphoma and multiple myeloma. Blood cells perform functions that are critical to human health, such as fighting off infections and preventing serious bleeding. When blood cells become cancerous, it can affect their production and ability to function.

The impact of blood cancers

**Every 3 minutes** someone in the US is diagnosed with a blood cancer.**1.3M people** in US are living with or are in remission from blood cancers.**Within 5 years** of diagnosis, more than one third of these patients will die, on average.

Addressing critical unmet medical need

Leveraging its collective heritage in oncology, AstraZeneca has established hematology as one of four key oncology disease areas of focus, and is accelerating development of a broad portfolio of potential blood cancer treatments.

3 therapies being investigated in 35+ late-stage clinical trials, exploring 10+ blood cancers

**Monotherapy** and combination therapy strategies for blood cancers and solid tumors

Investigational agents in pre-clinical through Phase II development

Partnering to deliver breakthrough therapies

AstraZeneca works with like-minded, science-led companies that contribute scientific capability, complementary technologies and promising molecules to our diverse pipeline.

Some of the compounds from AstraZeneca/MedImmune within this document refer to pipeline products that are still under development and as such are not approved by the US Food and Drug Administration (FDA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should under no circumstances be regarded as a recommendation for their use, safety or efficacy.

References